Tabrecta
What Tabrecta is used for
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Tabrecta
- Active substance
- capmatinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01EX17
- Marketing authorisation holder
- Novartis Europharm Limited
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Tabrecta
In India
- Capmatinib dihydrochloride monohydrate: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tabrecta used for?
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
What is the active substance in Tabrecta?
Tabrecta contains capmatinib.
Who makes Tabrecta?
The EU marketing authorisation holder is Novartis Europharm Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU